
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc. is demonstrating an attractive current valuation, as indicated by a recent net present value (NPV) analysis that suggests substantial upside potential from the current share price. The company is focused on developing cannabinoid-based formulations, with investigational drug assets like IGC-AD1 showing encouraging preclinical results in targeting key hallmarks of Alzheimer's disease. Additionally, the anticipation of further positive data and advancements in their drug development pipeline is expected to act as a catalyst for the stock's upward momentum.
Bears say
IGC Pharma Inc reported a net loss of $1.6 million, equating to an earnings per share (EPS) of $(0.02), which aligns with previous estimates but indicates ongoing financial challenges. The company faces several significant risks, including balance sheet liquidity concerns, potential failures of its investigational drugs in clinical trials, and hurdles related to regulatory approvals and commercialization. Additionally, external factors such as competition and shifting investor sentiment toward biotech stocks further contribute to the negative outlook for IGC Pharma's financial health and stock performance.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares